Status:
COMPLETED
High Resolution MRI Study for Prostate Cancer
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
19+ years
Phase:
NA
Brief Summary
This high resolution MRI (hrMRI), along with stand MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance. Changes in lesion size ...
Detailed Description
2.0 BACKGROUND AND RATIONALE Multiparametric MRI Multiparametric MRI combining T2-weighted, diffusion-weighted, and dynamic contrast enhanced (DCE) images is commonly employed for detection and local...
Eligibility Criteria
Inclusion
- Age over 18 years
- Patients diagnosed with clinically localized prostate cancer
- Low or Low-intermediate Risk Prostate cancer1 defined as:
- Pre-operative prostate specific antigen (PSA) ≤ 20.0 ng/ml
- Clinical stage cT1 or cT2
- Gleason score 3+3 or 3+4
- Patients choosing AS or already on AS as primary management strategy
- No previous treatment for prostate cancer with radiotherapy, chemotherapy, or hormonal therapy
- No contraindications for gadolinium enhanced MRI
Exclusion
- No exclusion criteria
Key Trial Info
Start Date :
September 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03292874
Start Date
September 13 2017
End Date
December 14 2022
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048